Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03301883
Recruitment Status : Recruiting
First Posted : October 4, 2017
Last Update Posted : October 30, 2020
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
This Phase IV, multicenter, single-arm, open-label study will evaluate the efficacy and safety of tocilizumab in Chinese participants with sJIA with persistent activity and an inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs) and steroid therapy.

Condition or disease Intervention/treatment Phase
Juvenile Idiopathic Arthritis Drug: Tocilizumab Drug: NSAIDs Drug: CSs Drug: MTX Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 74 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IV, Multicenter, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Tocilizumab in Chinese Patients With Systemic Juvenile Idiopathic Arthritis
Actual Study Start Date : April 26, 2018
Estimated Primary Completion Date : June 30, 2021
Estimated Study Completion Date : June 30, 2021


Arm Intervention/treatment
Experimental: Tocilizumab
Participants weighing greater than or equal to (>/=) 30 kilograms (kg) will receive tocilizumab 8 milligrams per kilogram (mg/kg) intravenous (IV) infusion every 2 weeks (Q2W), and participants weighing less than (<) 30 kg will receive tocilizumab 12 mg/kg IV infusion Q2W for 52 weeks. After Week 12, the dose of tocilizumab can be adjusted for non-transient changes in body weight (shifting from <30 to >/=30 kg) over a minimum of three consecutive dosing visits. MTX, NSAIDs, and oral corticosteroids (CSs) are permitted but not required during the study.
Drug: Tocilizumab
Tocilizumab will be administered as per the schedule specified in the arm description.
Other Name: RO4877533

Drug: NSAIDs
Participants may receive NSAIDs up to the maximum recommended stable daily dose. Study protocol does not enforce any particular NSAID.

Drug: CSs
Participants may receive CSs at a stable dose of 30 milligrams per day (mg/day) or 0.5 milligrams per kilogram per day (mg/kg/day), whichever is less. Study protocol does not enforce any particular CS.

Drug: MTX
Participants may receive MTX at a stable dose of less than or equal to (</=) 20 milligrams per square meter (mg/m^2).




Primary Outcome Measures :
  1. Percentage of Participants Achieving Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 (JIA ACR30) Response With Absence of Fever, at Week 12 [ Time Frame: Week 12 ]

Secondary Outcome Measures :
  1. Percentage of Participants Achieving JIA ACR30 Response With Absence of Fever, at Week 52 [ Time Frame: Week 52 ]
  2. Percentage of Participants With 30 Percent (%), 50%, 70%, and 90% Improvement From Baseline in JIA Core Set Parameters [ Time Frame: Baseline, Weeks 12, 24, and 52 ]
  3. Percentage of Participants With Inactive Disease Assessed According to Criteria for Inactive Disease and Clinical Remission of sJIA (Wallace et. al. 2011 Criteria) [ Time Frame: Weeks 24 and 52 ]
  4. Percentage of Participants With Clinical Remission Assessed According to Criteria for Inactive Disease and Clinical Remission of sJIA (Wallace et. al. 2011 Criteria) [ Time Frame: Week 52 ]
  5. Percentage of Participants With an Elevated High-Sensitivity C-Reactive Protein (hsCRP) Levels at Baseline Who Have Normal hsCRP Levels at Weeks 12, 24, and 52 [ Time Frame: Baseline, Weeks 12, 24, and 52 ]
  6. Mean Glucocorticoid Dose [ Time Frame: Baseline up to Week 52 ]
  7. Mean Methotrexate (MTX) Dose [ Time Frame: Baseline up to Week 52 ]
  8. Change From Baseline in Glucocorticoid Dose [ Time Frame: From Baseline to Week 52 ]
  9. Change From Baseline in MTX Dose [ Time Frame: From Baseline to Week 52 ]
  10. Pain Visual Analog Scale (VAS) Score [ Time Frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ]
  11. Change From Baseline in Pain VAS Score [ Time Frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ]
  12. Percentage of Participants Who Discontinue Permitted Concomitant Medication for sJIA [ Time Frame: Baseline up to Week 52 ]
  13. Percentage of Participants With Adverse Events (AEs) [ Time Frame: Baseline up to end of study (up to Week 60) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants meeting International League of Associations for Rheumatology (ILAR) classification for sJIA
  • Greater than (>) 6 months of documented persistent sJIA activity prior to screening
  • Active disease
  • hsCRP >4.3 milligrams per liter (mg/L) or 0.43 milligrams per deciliter (mg/dL)
  • Participant who has recovered from any symptomatic serositis for at least 30 days prior to the screening visit, and requires a dose of CSs at baseline of </=30 mg/day or </=0.5 mg/kg/day, whichever is less
  • Participants meeting one of the following: Participant who is not receiving MTX or discontinued MTX >/=4 weeks prior to baseline visit; participant who has been taking MTX >/=12 weeks immediately prior to the baseline visit and on a stable dose of </=20 mg/m^2 for >/=8 weeks prior to the baseline visit, together with either folic acid or folinic acid according to local standard of care
  • Participant who was never treated with biologics or, if was previously treated with biologics, discontinued etanercept (or Yisaipu, Qiangke, or Anbainuo) >/=2 weeks, infliximab or adalimumab >/=8 weeks, anakinra >/=1 week, or abatacept >/=12 weeks prior to the baseline visit
  • Participant who is not currently receiving oral CSs, or is taking oral CSs at a stable dose for >/=2 weeks prior to the baseline visit at </=30 mg/day or </=0.5 mg/kg/day, whichever is less
  • Participant who is not taking NSAIDs, or taking </=1 type of NSAID at a stable dose for >/=2 weeks prior to the baseline visit and is less than or equal to the maximum recommended daily dose

Exclusion Criteria:

  • Wheelchair bound or bedridden participant
  • Any other autoimmune, rheumatic disease, or overlap syndrome other than sJIA
  • Participant who is not fully recovered from recent surgery or <6 weeks since surgery at the time of screening visit; or planned surgery during the initial 12 weeks of the study
  • Lack of peripheral venous access
  • Any significant concurrent medical or surgical condition that would jeopardize the participant's safety or ability to complete the trial
  • Evidence of serious uncontrolled concomitant diseases
  • Asthma for which the participant has required the use of oral or parenteral CSs for >/=2 weeks within 6 months prior to the baseline visit
  • Known human immunodeficiency (HIV) infection or other acquired forms of immune compromise or congenital conditions characterized by a compromised immune system
  • Any active acute, subacute, chronic, or recurrent bacterial, mycobacterial, viral, or systemic fungal infection or opportunistic infection
  • Any major episode of infection requiring hospitalization or treatment during screening, treatment with IV antibiotics completing within 4 weeks of the screening visit, or oral antibiotics completing within 2 weeks of the screening visit
  • History of atypical tuberculosis (TB)
  • Active TB requiring treatment within 2 years prior to screening visit
  • Positive purified protein derivative (PPD) or T-spot test (interferon-gamma [IFN-γ]-based test) at screen
  • Positive for latent TB
  • History of reactivation or new onset of a systemic infection such as herpes zoster or Epstein-Barr virus (EBV) within 2 months of the screening visit
  • Hepatitis B surface antigen (Ag)- or hepatitis C antibody (Ab)-positive
  • History of macrophage activation syndrome (MAS) within 3 months prior to the screening visit
  • Evidence of active malignant disease or diagnosed malignancies
  • Uncontrolled diabetes mellitus
  • Previous treatment with tocilizumab
  • Intra-articular, intramuscular, IV, or long-acting CSs administration within 28 days prior to the baseline visit
  • Treatment with non-biologic disease-modifying antirheumatic drugs (DMARDs; other than MTX) within 6 weeks prior to the baseline visit
  • Treatment with leflunomide that was not followed by standardized cholestyramine washout and documented to be below the limit of detection prior to the baseline visit
  • Treatment with cyclophosphamide, etoposide (VP16) and statins within 90 days prior to the baseline visit
  • Treatment with growth hormone and androgens within 4 weeks prior to the baseline visit
  • Administration of IV immunoglobulin within 28 days prior to the baseline visit
  • Treatment with any cell-depleting therapies
  • Stem cell transplant at any time
  • Participant who has received live or attenuated vaccines within 4 weeks prior to the baseline visit, or intending to receive while on study drug or 3 months following the last dose of study drug

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03301883


Contacts
Layout table for location contacts
Contact: Reference Study ID Number: YA39368 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. and Canada) global-roche-genentech-trials@gene.com

Locations
Layout table for location information
China
Capital Institute of Pediatrics Recruiting
Beijing City, China, 100020
Beijing Children's Hospital, Capital Medical University; rheumatism Recruiting
Beijing City, China, 100045
The First Hospital of Jilin University Recruiting
Changchun City, China, 130021
Children's Hospital Chongqing Medical university Recruiting
Chongqing City, China, 400014
Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Pediatric Rheumatology division Recruiting
Guangzhou City, China, 510120
The Children's Hospibal ZheJiang University School of Medicine Recruiting
Hangzhou City, China, 310052
Chilren's hospital of nanjing medical university; Rheumatoid immunology Recruiting
Nanjing, China, 210000
Shanghai Children's Medical Center; Renal rheumatology Recruiting
Shanghai City, China, 200127
Children's Hospital of Fudan University Recruiting
Shanghai, China, 201102
The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical College Recruiting
Wenzhou, China, 325000
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche
Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT03301883    
Other Study ID Numbers: YA39368
First Posted: October 4, 2017    Key Record Dates
Last Update Posted: October 30, 2020
Last Verified: October 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Juvenile
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases